The DNA mismatch repair gene hMSH2 is a potent coactivator of oestrogen receptor α.

O Wada-Hiraike*1,3, T Yano1, T Nei1, Y Matsumoto1, K Nagasaka1, S Takizawa1, H Oishi1,3, T Arimoto1, S Nakagawa1, T Yasugi1, S Kato2,3 and Y Taketani1

1Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1 Bunkyo-ku, Tokyo 113-8655, Japan; 2SORST, Japan Science and Technology, Honcho 4-1-8, Kawaguchi, Saitama 332-0012, Japan; 3Institute of Molecular and Cellular Biosciences, The University of Tokyo, Yayoi 1-1-1 Bunkyo-ku, Tokyo 113-0034, Japan

*Correspondence: Dr O Wada-Hiraike, Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1 Bunkyo-ku, Tokyo 113-8655, Japan; E-mail: owada-tky@umin.ac.jp

Received 1 January 2005; revised 10 March 2005; accepted 5 April 2005; published online 10 May 2005

Keywords: hMSH2; HNPCC; ER α; ER β; coactivator; transactivation

The DNA mismatch repair gene hMSH2 is a potent coactivator of oestrogen receptor α.
80% of the hMSH2 mutations lead to premature termination of the hMSH2 gene product. The truncated hMSH2 gene product may lose its critical functions (Drotschmann et al, 1999), which is related to the development of HNPC.

Oestrogen receptor is a member of the nuclear hormone receptor gene superfamily and acts as a ligand-induced transcription factor (Mangelsdorf et al, 1995). Oestrogen receptor is stimulated by two distinct activation regions, activation function-1 (AF-1) and AF-2. Activation function-1, which is located in the N-terminal A/B domain, is constitutively activated in cell-type and promoter-specific manner (Metzger et al, 1995). Activation function-2 is located in the C-terminal ligand-binding domain and exerts a ligand-dependent transcriptional activation. Activation function-1 and AF-2 activate transcription independently and act synergistically (Lopez et al, 1999). Oestrogen receptor z contact the general transcription factors either directly or indirectly via coactivator proteins, including AF-1 coactivator p300 (Kobayashi et al, 2000) and p68/p72 (DEAD box protein) (Watanabe et al, 2001). The ligand-dependent activation of ER z requires ligand-dependent association of AF-2 coactivator complex, including p300/CPB, pCAF, the p60 family members SRC-1/TIF-2/pCIP/ AIB-1/GRIIP/ACTR (McKenna et al, 1999), the thyroid hormone receptor-associated proteins/the vitamin D receptor-interacting proteins (TRAP/DRIP) (Rachetz et al, 2000; Kang et al, 2002), the transformation/transcription domain-associated protein (TRRAP), and the histone acetyltransferase GCN5 (Yanagisawa et al, 2002).

We have recently revealed that breast cancer susceptibility gene 1 (BRCA1), hMSH2, and GCN5 formed a complex to work on DNA repair (unpublished data). Current studies have implicated DNA repair proteins, including the T:G mismatch specific thymine DNA glycosylase (Chen et al, 2003), and the xeroderma pigmentosum complementary group D (XPD) (Keriel et al, 2002) in the transcription regulation by nuclear receptors (NRs). On the basis of the report showing the transcriptional squelching between BRCA1 and ER z (Fan et al, 1999), we investigated the functional interaction between hMSH2 and ER z.

MATERIALS AND METHODS

Cell culture

Oestrogen receptor z/b-positive T-47D (HTB-133) and ER b-positive MDA-MB-231 (HTB-26) human breast cancer cell lines were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). Oestrogen receptor z-positive Ishikawa human endometrial cancer cell line was kindly provided by Dr M Nishida (Tsukuba University, Tsukuba, Japan), and hMSH2-deficient HEC95 human endometrial cancer cell line was a generous gift from Dr H Kuramoto (Kitsato University, Sagamihara, Japan). These cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Sigma Aldrich, St Louis, MO, USA) supplemented with 10% fetal bovine serum (Sigma Aldrich).

Immunoprecipitation

Formation of ER z/hMSH2 complex in Ishikawa cells and ER b/hMSH2, BRCA1–hMSH2 (Wang et al, 2001) complex in MDA-MB-231cells were analysed by co-immunoprecipitation using the specific antibody raised against human ER z (G-20), human ER b (H-150), and human BRCA1 (C-20), followed by immunoblotting using the anti-hMSH2 antibody (N-20). All the antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The 3 x 106 cells were suspended in 1000 ml of TNE buffer (10 mM Tris-HCl (pH 7.8), 1% Nonidet-P40, 0.15 M NaCl, 1 mM EDTA, 1 mM phenylmethylsulphonyl fluoride, and 1 mg ml-1 aprotinin). The cells were disrupted by repeated aspiration through 27-gauge needle and cellular debris were precipitated by centrifugation at 12,000 r.p.m. for 30 min at 4°C. The whole supernatant was applied for immunoprecipitation with 3 mg of the antibodies to ER z, ER b, BRCA1, or IgG. Then, 30 ml of protein G sepharoseTM 4 Fast Flow (Amersham Biosciences, Buckinghamshire, UK) was added, and subsequently the bound proteins were purified as a complex protein. After washing with TNE buffer four times, the interacting proteins were separated by 7.5% SDS–polyacrylamide gel electrophoresis, transferred onto HybondTM-ECLTM nitrocellulose membrane (Amersham Biosciences), and detected by Western blotting with the anti-hMSH2 antibody. ECL detection was performed according to the manufacturer’s recommendations.

Plasmid construction

TRAP220 and SRC-1 expression vectors were described previously (Fujita et al, 2003; Wada et al, 2004). Human MutS homologue 2 expression vector was constructed from human testis library (Clontech, Palo Alto, CA, USA). Fragments of hMSH2 were inserted into pcDNA FLAG vector derived from pcDNA 3 (Invitrogen, Carlsbad, CA, USA). Human ERz AF-1 (1–180), ER z AF-2 (263–595), ER b AF-1 (1–149), and ER b AF-2 (248–530) vectors were described previously (Fujita et al, 2003). Reporter constructs (17M b/17M z) have been described previously (Wada et al, 2004).

Glutathione-S-transferase-pulldown assay

Glutathione-S-transferase (GST) fusion proteins or GST alone were expressed in Escherichia coli and bound to glutathione-sepharose 4B beads (Amersham Biosciences). Immobilised GST-ER b AF-1 or AF-2 fusion proteins were preincubated for 30 min in NET buffer (20 mM Tris-HCl pH 7.5, 200 mM NaCl, 1 mM EDTA) with or without 17-b estradiol (10–6 M). The GST proteins were incubated at 4°C with [35S]methionine (Amersham Biosciences)-labeled proteins expressed by in vitro transcription using the TNT-coupled transcription–translation system (Promega Co., Madison, WI, USA). After 1 h incubation, unbound proteins were removed by washing the beads three times in NET buffer with 0.5% Nonidet P-40 and 1 mM phenylmethylsulphonyl fluoride. Specifically bound proteins were eluted by boiling in SDS sample buffer and analysed by 7.5–15% SDS–polyacrylamide gel electrophoresis and autoradiography. Polyacrylamide gels were stained briefly with Comassie Brilliant Blue to verify the loading of equal amounts of fusion proteins prior to drying and autoradiography.

Luciferase assay

At 2 days before transfection, the medium was changed to phenol red-free DMEM containing 5% charcoal stripped fetal bovine serum. Transfection was performed with PolyFect reagent (Qiagen, Inc., Chatsworth, CA, USA) according to the manufacturer’s recommendations. For luciferase assay, 250 pg 17M b/17M z plasmid was cotransfected with 250 ng pM ER z/AF-2 or pM ER b AF-2. Indicated expression vectors were also cotransfected with ER vectors. As an internal control to equalise transfection efficiency, 5 pg pRL CMV vector (Promega Co., Madison, WI, USA) was cotransfected in all the experiments. Individual transfections, each consisting of triplicate wells, were repeated at least three times (Wada et al, 2004).

RESULTS

ER z/b and hMSH2 interacts in vivo

To determine whether endogenous hMSH2 protein interacted with ER z, ER b, and BRCA1 in the cultured human cells, we performed immunoprecipitation assays by using the antibodies raised against ER z, ER b, and BRCA1. Oestrogen receptor z was immunopre-
cipated in Ishikawa cell lysate. Oestrogen receptor β and BRCA1 were immunoprecipitated in MDA-MB-231 cell lysate. Complex formation of the precipitated proteins was confirmed by Western blotting. Immunoblotting revealed the existence of hMSH2 in the cell lysate immunoprecipitates (Figure 1A(ii)), which supports our hypothesis that hMSH2 physically associates with ER α and ER β in living cells. These results were further confirmed by reciprocal immunoprecipitation with the specific antibody raised against hMSH2. Immunoblotting again revealed the existence of ER α and ER β (Figure 1A(ii)).

ER α and hMSH2 interact in vitro in a ligand-dependent manner, and ER β and hMSH2 interact in vitro in a ligand-independent manner

To address the functional importance of the hMSH2-ER α and hMSH2-ER β interaction, in vitro translated hMSH2 in the presence of [35S] methionine was incubated with GST-fused ER α/β AF-1 or ER α/β AF-2. As clearly shown in Figure 1B, the liganded GST-fused ER α AF-2 protein possessed the ability to retain hMSH2 on the column. On the other hand, GST-fused ER α AF-2 protein without the ligand, and GST-fused ER α AF-1 protein lacked the ability to retain hMSH2 on the column. Liganded ER α AF-2 possessed the ability to retain TRAP220, one of the coactivator of ER α. These data indicated that hMSH2 directly interacts with ER α AF-2 in a ligand-dependent manner, similar to TRAP220. Glutathione-S-transferase-fused ER β AF-2 protein possessed the ability to retain hMSH2 on the column regardless of the presence of ligand (Figure 1B). Glutathione-S-transferase-fused ER β AF-1 protein lacked the ability to retain hMSH2 on the column. These results indicated that hMSH2 directly interacts with ER β AF-2 in a ligand-independent manner.

Mapping of the region of hMSH2 that interacts with ER α AF-2 and ER β AF-2

To map the region of hMSH2 that interacted with ER α/β AF-2, a GST pulldown assay was performed using GST-fused ER α/β AF-2, and in vitro translated hMSH2 fragments (Figure 2). The FLAG-tagged hMSH2 fragments, abbreviated ‘F1’ (1–178), ‘F2’ (179–377), ‘F3’ (378–625), ‘F4’ (609–886), and ‘F5’ (793–934), were in vitro translated and tested for the interaction with ER α/β. Only F3 region of hMSH2 interacted with ER α AF-2 in a ligand-dependent manner. Thus, F3 of hMSH2 complexed with ER α via the hMSH3/hMSH6 interaction domain. Interestingly, the liganded ER α column did not retain F2, which contains LXXLL motifs thought to interact with liganded NRs (Heery et al, 1997; Voegel et al, 1998). F3 and F4 regions of hMSH2 interacted with ER β AF-2 in a ligand-independent manner. Thus, F3 and F4 of hMSH2 complexed with ER β via the hMSH3/hMSH6 interaction domain.

hMSH2 potentiates the transactivation function of ER α in a ligand-dependent manner

To examine the coactivator activity of hMSH2 in the transactivation function of ER α/β, a transient transfection assay was performed using a luciferase reporter plasmid driven by the β-globin promoter containing GAL4 DNA-binding domain. While ER α/GAL4 fusion protein (GAL-ER α AF-2) showed a ligand-dependent transactivation in human HEC59 endometrial cancer cells, a transient coexpression of hMSH2 led to an approximately 2.5-fold increase in the luciferase activity compared to that of GAL-ER α AF-2 alone (Figure 3). The promoted transactivation function by hMSH2 was comparable to that by AF-2 coactivators, SRC-1 and TRAP220. This enhancement of transactivation by hMSH2 was observed in hMSH2-deficient HEC59 cells, but not in the other cell lines, MDA-MB-231 and T-47D (data not shown). The ligand-induced transactivation was not promoted by hMSH2 when GAL-ER β AF-2 was used (Figure 3), as expected from the in vitro ER α/β experiments. This again suggested a significant role of hMSH2 in the ligand-dependent transactivation function of ER α.
DISCUSSION

We showed that endogenous ERα/β associated with wild-type hMSH2 in the cultured human cells. Immunoblotting revealed the existence of hMSH2 in the cell lysate immunoprecipitates, which was confirmed by reciprocal immunoprecipitation with the specific antibody raised against hMSH2. The direct interaction between ERα/β and hMSH2 was investigated by GST pulldown assays. The GST-fused ERα AF-2 protein showed the ability to retain hMSH2 in a ligand-dependent manner. F3 region of hMSH2 interacted with ERα AF-2 in a ligand-dependent manner, which was supported by the findings that ERα alone potently enhanced hMSH2 transactivation function. In contrast, F3 and F4 regions of hMSH2 interacted with ERβ AF-2 in a ligand-independent manner, and ERβ lacked the ability to enhance hMSH2 transactivation function. These results indicated that the ERα/β-containing complexes might play a role in the MMR system of hMSH2.

Ligand-dependent interaction of hMSH2 was identified as a unique property because hMSH2 directly binds to ERα AF-2 as if hMSH2 acts as an ER coactivator. Although hMSH2 has three NR recognition motifs (LXXLL, NR box), these motifs have no significant role in the binding of ERα and ERβ. Given that hMSH2 may promote gene regulation with ERs, and that the mutations in hMSH2 may lead to an altered ERα-dependent gene regulation and an altered tumorigenesis in oestrogen-dependent cancers (presumably through the modulation of ER-mediated oestrogen signalling), the interaction between ERα/β and hMSH2 may partially account for the relationship between HNPCC and oestrogen-dependent extracolonic tumours such as endometrial cancer. Our results also indicated that hMSH2 competed with ERα in terms of transcriptional control via the hMSH3/hMSH6 interaction domain of hMSH2, which suggests the possibility that the common coactivator complexes of ER, including the p160 family complex, TRAP/DRIP complex and TFTC complex, might have a functional relationship with the MMR complex.

Figure 2  Mapping of the ERα/β-interacting region of hMSH2. A schematic diagram of the structure of hMSH2 is shown. ‘F1’, ‘F2’, ‘F3’, ‘F4’, and ‘F5’ fragments of hMSH2 were in vitro translated. In view of the result of Figure 1, the fragments of hMSH2 and GST-ERα/β AF-2 were tested for detection. The mixtures were washed and subjected to SDS–PAGE and then visualised by autoradiography.
Oestrogen stimulates diverse biological effects in humans, and many of these effects result from a direct interaction of oestrogen with an NR that activates the expression of genes encoding proteins with important biological functions. Oestrogen has a mitogenic action in hormone-sensitive tissues such as the uterus. In addition to this action, oestrogen possesses carcinogenic activity. Prolonged exposure to oestrogen without opposing by progesterone is considered to cause endometrial hyperplasia and endometrioid adenocarcinoma in relatively young women. The progesterone is considered to cause endometrial hyperplasia and activity. Prolonged exposure to oestrogen without opposing by progesterone is considered to cause endometrial hyperplasia and endometrioid adenocarcinoma in relatively young women. The interaction between ER α/β and hMSH2 might have a significant role in the pathogenesis of endometrial cancer. Recently, it was reported that not only tamoxifen, a selective oestrogen receptor modulator (SERM) used in the treatment of breast cancer, but also oestrogen derivatives possess a high mutagenic potential (Mizutani et al., 2004), which is attained by two mechanisms. First, DNA replication blocks may cause chromosomal breaks and lead to translocation or large deletion. Second, the employment of error-prone translesion DNA synthesis polymerases to bypass DNA damage is likely to result in an accumulation of point mutations. On the other hand, withdrawal of oestrogen may increase a risk of microsatellite instability-positive colon cancer based on the epidemiological data (Slattery et al., 2001). Considering the present data, ER itself may have a functional role in DNA MMR. Especially, ER β, which is expressed in colon cancer (Gustafsson, 2003), may have a potent role through the ligand-independent interaction with hMSH2.

The present study showed that ER α/β bound directly to wild-type hMSH2. Considering the fact that most mutations found in the patients of HNPCC result in a premature truncation of hMSH2, the loss of hMSH3/hMSH6 interaction domain in hMSH2 may result in a loss of interaction between ER α/β and hMSH2. In this respect, the functional interaction between ERα/β and hMSH2 may be required to prevent or promote the progression in the pathogenesis of endometrial cancer complicating HNPCC. Our transient transfection assay showed that the MMR complex clearly served as a coactivator complex in the promoters of ER α target genes because hMSH2 enhanced ER α-mediated ligand-dependent transactivation function. Further investigations should be performed to elucidate the molecular mechanisms that underlie the formation of ERα/β/hMSH2 complexes in normal cell growth, thereby revealing hMSH2 as a tumour suppressor in oestrogen-responsive organs, especially the endometrium. In conclusion, these results suggest that the failure of binding between hMSH2 and ER α/β may be a key event in cancer predisposition.

ACKNOWLEDGEMENTS
This study was supported by a Grant-in-aid (No. 16790939, OW-H) for Scientific Research from the Ministry of Education, Science and Culture, Japan.

REFERENCES
Ban C, Junop M, Yang W (1999) Transformation of MutLI by ATP binding and hydrolysis: a switch in DNA mismatch repair. Cell 97: 85–97
Bubb VJ, Curtis LJ, Cunningham C, Dunlop MG, Carothers AD, Morris RG, White S, Bird CC, Wyllie AH (1996) Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene 20: 2641–2649
Chen D, Lucey MJ, Phoenix F, Lopez-Garcia J, Hart SM, Losson R, Buluwela L, Coombes RC, Chambon P, Schar P, Ali S (2003) T:G mismatch-specific thymine-DNA glycosylase potentiates transcription of estrogen-regulated genes through direct interaction with estrogen receptor alpha. J Biol Chem 278: 38586–38592
Drotschmann K, Clark AB, Tran HT, Resnick MA, Gordenin DA, Kunkel TA (1999) Mutator phenotypes of yeast strains heterozygous for mutations in the MSH2 gene. Proc Natl Acad Sci USA 96: 2970–2975

Figure 3  Activation of transcription by ER α AF-2 by the overexpression of hMSH2 in a ligand-dependent manner. HEC59 cells were transfected with pM ER α/β AF-2 (250 ng), 17M8 β-globin-luc (250 ng), pRL CMV-Luc (5 ng), pCDNA (100 ng), pCDNA hMSH2 (100 ng), pCDNA SRC-1 (100 ng), and pCDNA TRAP220 (100 ng) in the presence of 17β estradiol at 10−8 M, and cell extracts were used for luciferase assay. Results are shown as the mean ± s.d. SRC-1, TRAP 220, and hMSH2 caused a ligand-dependent potentiation of the ER α transactivation function.
Fan, S., Wang, J., Yuan, R., Ma, Y., Meng, Q., Erdos, M.R., Pestell, R.G., Yuan, F., Auborn, K.J., Goldberg, I.D., Rosen, E.M. (1999) BRCA1 inhibition of estrogen receptor signaling in transfected cells. *Science* 284: 1354–1356

Fishel, R., Lescoe, M.K., Rao, M.R., Copeland, N.G., Jenkins, N.A., Garber, J., Kane, M., Kolodner, R. (1993) The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. *Cell* 73: 1027–1038

Fujita, T., Kobayashi, Y., Wada, O., Tateishi, Y., Kitada, L., Yamamoto, Y., Takashima, H., Murayama, A., Yano, T., Baba, T., Kato, S., Kawabe, Y., Yanagisawa, J. (2003) Full activation of estrogen receptor alpha activation function-1 induces proliferation of breast cancer cells. *J Biol Chem* 278: 26704–26714

Glickman, B.W., Radman, M. (1980) *Escherichia coli* mutator mutants deficient in methylation-instructed DNA mismatch correction. *Proc Natl Acad Sci USA* 77: 1063–1067

Gustafsson, J.A. (2003) What pharmacologists can learn from recent advances in estrogen signalling. *Trends Pharmacol Sci* 24: 479–484

Heery, D.M., Kalkhoven, E., Hoare, S., Parker, M.G. (1997) A signature motif in transcriptional co-activators mediates binding to nuclear receptors. *Nature* 387: 733–736

Kang, Y.K., Guermah, M., Yuan, C.X., Roeder, R.G. (2002) The TRAP/Mediator coactivator complex interacts directly with estrogen receptors alpha and beta through the TRAP220 subunit and directly enhances estrogen receptor function *in vitro*. *Proc Natl Acad Sci USA* 99: 2642–2647

Keriel, A., Stary, A., Sarasin, A., Rochette-Egly, C., Egly, J.M. (2002) XPD mutations prevent TFIIF-dependent transcriptional activation by nuclear receptors and phosphorylation of RARalpha. *Cell* 1: 125–135

Kobayashi, Y., Kitamoto, T., Masuhiro, Y., Watanabe, M., Kase, T., Metzger, D., Yanagisawa, J., Kato, S. (2000) p300 mediates functional synergism between AF-1 and AF-2 of estrogen receptor alpha and beta by interacting directly with the N-terminal A/B domains. *J Biol Chem* 275: 15645–15651

Leach, F.S., Nicolaides, N.C., Papadopoulos, N., Liu, B., Jen, J., Parsons, R., Pelomaki, P., Sistonen, P., Aaltonen, L.A., Nyström-Lahti, M., Guan, X.Y., Zhang, J., Melzer, P.S., Yu, K.W., Kao, F.T., Chen, D.J., Cerosaletti, K.M., Fournier, R.E.K., Todd, S., Lewis, T., Leach, R.J., Naylor, S.L., Weissenbach, J., Mecklin, J.P., Järvinen, H., Petersen, G.M., Hamilton, S.R., Green, J., Jass, J., Watson, P., Lynch, H.T., Trent, J.M., Chapelle, A., Kinzler, K.W., Vogelstein, B. (1993) Mutations of the MTS homolog in hereditary nonpolyposis colorectal cancer. *Cell* 75: 1215–1225

Lopez, G.N., Webb, P., Shinsako, J.H., Baxter, J.D., Greene, G.L., Kushner, P.J. (1999) Titration by estrogen receptor activation function-2 of targets that are downstream from coactivators. *Mol Endocrinol* 13: 897–909

Mangelsdorf, D.J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., Evans, R.M. (1995) The nuclear receptor superfamily: the second decade. *Genes Dev* 9: 835–839

Marsischky, G.T., Filosi, N., Kane, M.F., Kolodner, R. (1996) Redundancy of *Saccharomyces cerevisiae* MSH3 and MSH6 in MSH2-dependent mismatch repair. *Genes Dev* 10: 407–420

McKenna, N.J., Lanz, B.B., O’Malley, B.W. (1999) Nuclear receptor coregulators: cellular and molecular biology. *Endocr Rev* 20: 321–344

Metzger, D., Ali, S., Bornert, J.M., Chambon, P. (1995) Characterization of the amino-terminal transcriptional activation function of the human estrogen receptor in animal and yeast cells. *J Biol Chem* 270: 9535–9542

Mitchell, R.J., Farrington, S.M., Dunlop, M.G., Campbell, H. (2001) Mismatch repair genes hMLH1 and hMSH2 and colorectal cancer. *Am J Epidemiol* 156: 885–902

Mizutani, A., Okada, T., Shibutani, S., Sonoda, E., Hochegger, H., Nishigori, C., Miyachi, Y., Takeda, S., Yamazoe, M. (2004) Extensive chromosomal breaks are induced by tamoxifen and estrogen in DNA repair-deficient cells. *Cancer Res* 64: 3144–3147

Modrich, P. (1997) Strand-specific mismatch repair in mammalian cells. *J Biol Chem* 272: 24727–24730

Rachez, C., Gamble, M., Chang, C.P., Atkins, G.B., Lazar, M.A., Freedman, L.P. (2000) The DRIP complex and SRC-1/p160 coactivators share similar nuclear receptor binding determinants but constitute functionally distinct complexxes. *Mol Cell Biol* 20: 2718–2726

Rodriguez-Bigas, M.A., Lee, P.H., O’Malley, L., Weber, T.K., Suh, O., Anderson, G.R., Petrelli, N.J. (1996) Establishment of a hereditary nonpolyposis colorectal cancer registry. *Dis Colon Rectum* 39: 649–653

Slattery, M.L., Potter, J.D., Curtin, K., Edwards, S., Ma, K.N., Anderson, K., Schaffer, D., Samowitz, W.S. (2001) Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. *Cancer Res* 61: 126–130

Voegel, J., Heine, M.J., Tini, M., Vivat, V., Chambon, P., Gronemeyer, H. (1998) The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transcription through CBP binding-dependent and -independent pathways. *EMBO J* 17: 507–519

Wada, O., Oishi, H., Takada, I., Yanagisawa, J., Yano, T., Kato, S. (2004) BRCA1 function mediates a TRAP/DRIP complex through direct interaction with TRAP220. *Oncogene* 23: 6000–6005

Wang, Q., Zhang, H., Guerrette, S., Chen, J., Mazurek, A., Wilson, T., Slupianek, A., Skorski, T., Fishel, R., Greene, M.I. (2001) Adenosine nucleotide modulates the physical interaction between hMSH2 and BRCA1. *Oncogene* 20: 4640–4649

Watanabe, M., Yanagisawa, J., Kitagawa, H., Takeyama, K., Ogawa, S., Arazo, Y., Suzawa, M., Kobayashi, Y., Yano, T., Yoshikawa, H., Masuhiko, Y., Kato, S. (2001) A subfamily of RNA-binding DEAD-box proteins acts as an estrogen receptor alpha coactivator through the N-terminal activation domain (AF-1) with an RNA coactivator, SRA. *Cancer Res* 61: 1341–1352

Yanagisawa, J., Kitagawa, H., Yanagida, M., Wada, O., Ogawa, S., Nakagomi, M., Oishi, H., Yamamoto, Y., Nagasawa, H., McMahon, S.R., Cole, M.D., Tora, L., Takahashi, N., Kato, S. (2002) Nuclear receptor function requires a TFFC-type histone acetyl transferase complex. *Mol Cell* 9: 553–562